alogliptin and metformin hydrochloride
alogliptin and metformin hydrochloride is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: alogliptin and metformin hydrochloride; Generic name: ALOGLIPTIN AND METFORMIN HYDROCHLORIDE; Manufacturer: Padagis Israel Pharmaceuticals Ltd.
| Brand name | alogliptin and metformin hydrochloride |
|---|---|
| Generic name | ALOGLIPTIN AND METFORMIN HYDROCHLORIDE |
| Manufacturer | Padagis Israel Pharmaceuticals Ltd |
| Used for | 1 INDICATIONS AND USAGE Alogliptin and metformin HCl tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Alogliptin and metformin HCl tablets are a combination of alogliptin, a dipeptidyl-peptidase-4 (DPP-4) inhibitor and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: Should not be used in patients with type 1 diabetes mellitus. ( 1 ) Limitations of Use Alogliptin and metformin HCl tablets should not recommended for use in patients with type 1 diabetes mellitus. |
| Dosage | 2 DOSAGE AND ADMINISTRATION Individualize the starting dosage based on the patient's current regimen. ( 2.1 ) Given orally twice daily with food. ( 2.1 ) Adjust the dosage based on effectiveness and tolerability while not exceeding the maximum recommended daily dosage of 25 mg alogliptin and 2000 mg metformin HCl. ( 2.1 ) Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR). ( 2.2 ) Do not use in patients with eGFR below 60 mL/min/1.73 m 2 . Alogliptin and |
| Warnings | WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (greater than 5 mmol/L), anion gap acidosis (without evi |
| Active ingredient(s) | ALOGLIPTIN BENZOATE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14d98490-4f8f-4d2f-a4e9-7a3d7a0199ba |